BB-83698
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H584131

CAS#: 325795-25-3

Description: BB-83698 is a peptide deformylase inhibitor and potent antimicrobial with excellent activity against streptococci and Moraxella catarrhalis strains.

Chemical Structure

img
BB-83698
CAS# 325795-25-3
Instruction

Theoretical Analysis

Hodoodo Cat#: H584131
Name: BB-83698
CAS#: 325795-25-3
Chemical Formula: C28H42N4O6
Exact Mass: 530.31
Molecular Weight: 530.666
Elemental Analysis: C, 63.37; H, 7.98; N, 10.56; O, 18.09

Price and Availability

Size Price Availability Quantity
1mg USD 190 Ready to ship
5mg USD 550 Ready to ship
10mg USD 950 Ready to ship
25mg USD 1650 Ready to ship
Bulk inquiry

Synonym: BB-83698; BB 83698; BB83698

IUPAC/Chemical Name: Cyclopentanepropanamide, N-((1S)-1-((4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)carbonyl)-2,2-dimethylpropyl)-alpha-((formylhydroxyamino)methyl)-, (alphaR)-

InChi Key: IBEANEPZNLVRRY-RCZVLFRGSA-N

InChi Code: InChI=1S/C28H42N4O6/c1-28(2,3)25(29-26(34)22(17-32(36)18-33)14-20-6-4-5-7-20)27(35)31-12-10-30(11-13-31)16-21-8-9-23-24(15-21)38-19-37-23/h8-9,15,18,20,22,25,36H,4-7,10-14,16-17,19H2,1-3H3,(H,29,34)/t22-,25-/m1/s1

SMILES Code: O=C(N[C@H](C(N1CCN(CC2=CC=C(OCO3)C3=C2)CC1)=O)C(C)(C)C)[C@@H](CN(C=O)O)CC4CCCC4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: BB-83698 is a peptide deformylase inhibitor and potent antimicrobial.
In vitro activity: BB-83698 demonstrated potent in vitro activity against all of the strains, regardless of preexisting resistance mechanisms (MICs, 0.06 to 0.25 μg/ml) (Table 1). Reference: Antimicrob Agents Chemother. 2004 Jan;48(1):80-5. https://pubmed.ncbi.nlm.nih.gov/14693522/
In vivo activity: Mice infected with penicillin-susceptible and macrolide-resistant strain P-6254 (erythromycin MIC, 1,024 μg/ml) had 10-day survival rates of 100% when they were treated with BB-83698 at 80 mg/kg/12 h or 160 mg/kg/24 h starting at 6 h postinfection. Comparator mice treated with erythromycin or azithromycin at 100 mg/kg/12 h had 10-day survival rates of only 30% (Fig. 1B). Treatment with amoxicillin at 5 mg/kg protected 80% of mice. Reference: Antimicrob Agents Chemother. 2004 Jan;48(1):80-5. https://pubmed.ncbi.nlm.nih.gov/14693522/

Preparing Stock Solutions

The following data is based on the product molecular weight 530.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Azoulay-Dupuis E, Mohler J, Bédos JP. Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother. 2004 Jan;48(1):80-5. doi: 10.1128/AAC.48.1.80-85.2004. PMID: 14693522; PMCID: PMC310171.
In vitro protocol: 1. Azoulay-Dupuis E, Mohler J, Bédos JP. Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother. 2004 Jan;48(1):80-5. doi: 10.1128/AAC.48.1.80-85.2004. PMID: 14693522; PMCID: PMC310171.
In vivo protocol: 1. Azoulay-Dupuis E, Mohler J, Bédos JP. Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother. 2004 Jan;48(1):80-5. doi: 10.1128/AAC.48.1.80-85.2004. PMID: 14693522; PMCID: PMC310171.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sangshetti JN, Khan FA, Shinde DB. Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. Curr Med Chem. 2015;22(2):214-36. Review. PubMed PMID: 25174923.

2: Guay DR. Drug forecast - the peptide deformylase inhibitors as antibacterial agents. Ther Clin Risk Manag. 2007 Aug;3(4):513-25. PubMed PMID: 18472972; PubMed Central PMCID: PMC2374925.

3: Wang Q, Wang J, Cai Z, Xu W. Prediction of the binding modes between BB-83698 and peptide deformylase from Bacillus stearothermophilus by docking and molecular dynamics simulation. Biophys Chem. 2008 May;134(3):178-84. doi: 10.1016/j.bpc.2008.02.003. Epub 2008 Feb 16. PubMed PMID: 18321635.

4: Khurdayan V, Bozzo J, Sorbera L. Chronicles in drug discovery. Drug News Perspect. 2005 Jun;18(5):332-6. PubMed PMID: 16193105.

5: Chen D, Yuan Z. Therapeutic potential of peptide deformylase inhibitors. Expert Opin Investig Drugs. 2005 Sep;14(9):1107-16. Review. PubMed PMID: 16144495.

6: Jain R, Chen D, White RJ, Patel DV, Yuan Z. Bacterial Peptide deformylase inhibitors: a new class of antibacterial agents. Curr Med Chem. 2005;12(14):1607-21. Review. PubMed PMID: 16022661.

7: Johnson KW, Lofland D, Moser HE. PDF inhibitors: an emerging class of antibacterial drugs. Curr Drug Targets Infect Disord. 2005 Mar;5(1):39-52. Review. PubMed PMID: 15777197.

8: Ramanathan-Girish S, McColm J, Clements JM, Taupin P, Barrowcliffe S, Hevizi J, Safrin S, Moore C, Patou G, Moser H, Gadd A, Hoch U, Jiang V, Lofland D, Johnson KW. Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob Agents Chemother. 2004 Dec;48(12):4835-42. PubMed PMID: 15561864; PubMed Central PMCID: PMC529202.

9: Lofland D, Difuntorum S, Waller A, Clements JM, Weaver MK, Karlowsky JA, Johnson K. In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698. J Antimicrob Chemother. 2004 Apr;53(4):664-8. Epub 2004 Feb 18. PubMed PMID: 14973152.

10: Azoulay-Dupuis E, Mohler J, Bédos JP. Efficacy of BB-83698, a novel peptide deformylase inhibitor, in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother. 2004 Jan;48(1):80-5. PubMed PMID: 14693522; PubMed Central PMCID: PMC310171.

11: Waller AS, Clements JM. Novel approaches to antimicrobial therapy: peptide deformylase. Curr Opin Drug Discov Devel. 2002 Sep;5(5):785-92. Review. PubMed PMID: 12630299.

12: Dubreuil L. [Peptide-deformylase inhibitors, a new class of antibiotics]. Presse Med. 2002 Nov 30;31(38):1810-2. French. PubMed PMID: 12497724.

13: Wise R, Andrews JM, Ashby J. In vitro activities of peptide deformylase inhibitors against gram-positive pathogens. Antimicrob Agents Chemother. 2002 Apr;46(4):1117-8. PubMed PMID: 11897602; PubMed Central PMCID: PMC127088.